Phlow

Executive Summary

Phlow, founded in 2020 and headquartered in Richmond, Virginia, is a U.S.-based pharmaceutical company dedicated to securing the domestic supply chain for essential generic medicines and active pharmaceutical ingredients (APIs). Leveraging advanced manufacturing and drug delivery technologies, Phlow focuses on producing critical drugs for infectious diseases and small molecules, aiming to reduce reliance on foreign suppliers and mitigate drug shortages. The company was launched with a mission to enhance national health security, and it has positioned itself as a key player in the Biden administration’s efforts to reshore pharmaceutical production. Phlow's innovative continuous manufacturing platform enables cost-effective, high-quality production of complex generic medicines, addressing vulnerabilities exposed during the COVID-19 pandemic. While still in its early stages with no disclosed funding or revenue, Phlow has garnered attention from government agencies and industry partners for its potential to transform generic drug manufacturing.

Upcoming Catalysts (preview)

• Q3 2026Securing additional BARDA or HHS contract for pandemic preparedness APIs70% success
• Q4 2026FDA approval or tentative approval for a new generic essential medicine60% success
• Q2 2026Announcement of manufacturing facility expansion or partnership with a major generic drugmaker75% success